NASDAQ: BNOXBionomics Limited Stock
$2.22+0.04 (+1.83%)
Updated May 31, 2023
BNOX Price
$2.22
Fair Value Price
N/A
Market Cap
$19.56M
52 Week Low
$1.80
52 Week High
$10.90
P/E
-0.01x
P/B
0.59x
P/S
197.6x
PEG
N/A
Dividend Yield
N/A
Revenue
$181.82k
Earnings
-$16.72M
Gross Margin
100%
Operating Margin
-9,513.66%
Profit Margin
-9,450.2%
Debt to Equity
0.18
Operating Cash Flow
-$12M
Beta
0.1
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
BNOX Overview
Bionomics Ltd is a clinical-stage biopharmaceutical company focused on drug candidates to transform the lives of patients suffering from serious central nervous system disorders. The company's lead candidate, BNC210, is a treatment for Social Anxiety Disorder and Post-Traumatic Stress Disorder. Bionomics was incorporated in 1996 and is based in Eastwood, Australia.
Zen Score
–
Industry Average (26)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how BNOX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
BNOX is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
BNOX is good value based on its book value relative to its share price (0.59x), compared to the US Biotechnology industry average (5.14x)
P/B vs Industry Valuation
BNOX is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more BNOX due diligence checks available for Premium users.
Be the first to know about important BNOX news, forecast changes, insider trades & much more!
BNOX News
Valuation
BNOX fair value
Fair Value of BNOX stock based on Discounted Cash Flow (DCF)
Price
$2.22
Fair Value
$14.31
Undervalued by
84.48%
BNOX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
BNOX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.01x
Industry
11.81x
Market
54.01x
BNOX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.59x
Industry
5.14x
BNOX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
BNOX's financial health
Profit margin
Revenue
$0.0
Net Income
$0.0
Profit Margin
0%
BNOX's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
BNOX's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$37.8M
Liabilities
$5.8M
Debt to equity
0.18
BNOX's short-term assets ($22.86M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
BNOX's short-term assets ($22.86M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
BNOX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
N/A
Investing
N/A
Financing
N/A
BNOX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
BNOX vs Biotech Stocks
Bionomics Limited Stock FAQ
©2023 WallStreetZen
Company
AboutBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.